President’s Perspective May 2017

Dear Colleagues,

Two months ago, I was privileged to speak at the 2017 meeting of the Royal College of Obstetricians and Gynaecologists’ (RCOG) in Cape Town about our global curriculum and training programme. At the same meeting, our former President, Lynnette Denny gave a wonderful plenary lecture highlighting the huge health care inequalities between the first and third worlds and emphasised that a diagnosis of cervical cancer, the leading cause of death of women from cancer in emerging countries, leads to loss of employment and income and a major deterioration of living standards.

Since few countries have a nationalised health system, payment for cancer care further pushes women and their families into severe poverty with a significant increase in food insecurity, loss of housing and major absences of children from school. And we all know that education is really the best tool to lead children out of poverty.

In many poor communities, the death of a mother is a major determinant of survival of her infants and children. One telling statistic from Bangladesh noted that cumulative survival from birth to 10 years was only 24% in families where the mother died before the child’s 10th birthday vs. 89% in those whose mothers did not die. How can we not be moved?

Lyn described cancer care in developing countries as ‘abysmal’ and unrecognised as a public health problem. In Africa the incidence to mortality ratio of cancer is 80% compared with 36% in wealthy countries. She highlighted lack of health care and training as important contributors to this awful statistic.

Tanzania is another example where lack of trained personnel and lack of equipment leads to desperate outcomes. For over 20,000 new cases of cancer annually there is one medical oncologist, four radiation oncologists, two physicists and an estimated 5 pathologists. Needless to say trained gynaecological oncologists are few on the ground, if at all.

Africa is not alone when we think of these terrible statistics.

So where does IGCS stand in all of this? Do we have a responsibility to try and change this disparity or is it too hard and best dealt with by someone else?

The answer is of course, that as caregivers and global citizens we do indeed have such a responsibility and that we need to show leadership and commitment. We undoubtedly can make a difference in the arena of education and training. After all, our mission revolves around improving outcomes for women with gynaecological cancers through teaching and training.

For us in the first world, it is time to give back.

The best way for us to do this is to support the IGCS Global Curriculum and Mentorship Programme. This programme depends on volunteer mentors being willing to regularly assess our trainees progress online, spend 1-2 weeks over a two-year period visiting them in their own training institutions and being involved in their exit examination.

By ‘twinning’ mentors and their institutions with training sites we hope that an ongoing rapport and willingness to help will make a huge difference to the care of women in under-developed countries.

In the next few months, IGCS will be reaching out to our members to assess just how many will be willing to join this programme and give back. I encourage you to ponder how well-off you really are and have become, often as a result of your professional status. It’s time for a change. It really is time to give back. Let IGCS lead the way. Please. 


Michael Quinn, MA, MGO
2016-2018 IGCS President

Gynecologic Oncology News & Updates

A compilation of news articles in the field of gynecologic oncology and recent scientific studies

Impact of prophylactic HPV vaccination on oral HPV infections among young adults in the US
May 20, 2017: Abstract to be presented at the 2017 ASCO Meeting finds that the “HPV vaccination substantially reduced vaccine-type oral HPV infection prevalence among young adults (ages 18-33 years) in the US population during 2011-2014. However, due to low vaccine uptake, population-level effectiveness was modest overall and particularly low in men.” Read the abstract.

Vaccine reduces HPV prevalence in teens, young adults
May 9, 2017: Medpage today reports the prevalence of HPV has fallen among young women in the U.S. since vaccination was recommended in 2006; first evidence that herd immunity protects unvaccinated individuals. Read the article.

When early-stage vulvar cancer recurs, the prognosis is poor
March 30, 2017: Watch this video interview with Dr. Rebecca Stone regarding the retrospective, multi-institutional cohort study examining stage IB vulvar cancer

How to start an oncology sexual health clinic
March 30, 2017: Watch this video interview with Joanne Rash, PA-C regarding a successful model to integrate sexual health into cancer care.

Non-Drug therapies found best for managing cancer fatigue
March 29, 2017: Behavioral therapies were significantly better than drugs for improving cancer-related fatigue during and after treatment, and should be prescribed as first-line treatments, according to a meta-analysis. Read more.

Vermillion announces publication of ovarian cancer symptoms index study
March 29, 2017: The original research titled, “Evaluation of a Validated Biomarker Test in Combination With a Symptom Index to Predict Ovarian Malignancy,” by Renata R. Urban, MD, Alan Smith, MS, Kathy Agnew, Vinicius Bonato, PhD, and Barbara A. Goff, MD, was acceptend for publication in the International Journal of Gynecological Cancer. Read the press release.

FDA grants Lynparza priority review for maintenance treatment of ovarian cancer
March 28, 2017: The new drug application for olaparib includes data from the phase III SOLO-2 trial presented at the SGO Annual Meeting. The FDA is expected to make a decision on this drug by the third quarter of 2017. Read more.

Promoting minimally invasive surgery for endometrial CA ‘should be a priority’
March 28, 2017: “The phase III Laparoscopic Approach to Cancer of the Endometrium (LACE) trial in women with stage I endometrial cancer showed nearly identical rates of disease-free survival at 4.5 years with total laparoscopic hysterectomy (TLH) versus total abdominal hysterectomy (TAH) (81.3% versus 81.6%, respectively, P=0.007), meeting prespecified criteria for equivalence.” MedPage Today interviews Dr. Andreas Obermair and Dr. Jason Wright. Read more.

Parental self-persuasion in low-income groups improves HPV vaccination rates
March 28, 2017: Study guides parents to consider why HPV vaccination is important and explain it’s benefit in their own words. See more.

FDA approves Zejula for maintenance treatment of gynecologic cancers
March 27, 2017: The FDA  approved niraparib for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers who achieved complete or partial response to platinum-based chemotherapy. Read more.

Ten years on, Professor Ian Frazer recalls ‘lucky’ discovery of cervical cancer vaccine
March 25, 2017: Professor Frazer recently spoke at the World Science Festival in Brisbane, Australia and was interviewed regarding his team’s discovery of the cervical cancer vaccine. Read the highlights from the interview.

Adjuvant and systemic therapy for rare tumors of the uterus and cervix
March 25, 2017: HemOnc Today offers practical advice on the treatment of rare diseases of the uterus and cervix by summarizing the latest research in a commentary written by Drs. Erin Crane, Jubilee Brown and Wendel Naumann. Read the commentary.

What all women need to know about gynecologic cancers
March 24, 2017: Health reporter Diane Atwood writes about her friend’s experience with stage III fallopian tube cancer and interviews gynecologic oncologist, Dr. Emmanuel Soultanakis, providing a complete summary of signs, symptoms and risk factors for gynecologic cancers. Read the blog.

Cancer survivors more likely to have preterm birth, cesarean delivery
March 23, 2017: Dr. Hazel B. Nichols is interviewed by HemOnc Today regarding her research that suggests women treated with chemotherapy may have increased risk for preterm birth in the future. Read the interview.

Combination yields ‘promising’ results for recurrent, BRCA-deficient ovarian cancer
March 23, 2017: An interview with Dr. Sarah Adams (University of New Mexico) regarding the phase 2 clinical trial studying combination treatment of olaparib (lynparza, AstraZeneca) and tremellimumab. Read the interview.

A call for molecular profiling in uterine carcinosarcoma
March 22, 2017: OncLive interviews Dr. Douglas Levine regarding the recent published paper in Cancer Cell, which charted the biology of 57 patients with uterine carcinosarcoma. Dr. Levine states that the “results really call for molecular profiling of this rare-type of tumor.” Read the interview.

Implementation of cervical cancer screening in developing countries
March 21, 2017: OncLive interviews Dr. Ann Marie Beddoe regarding her study implementing cervical cancer screening in Limpopo, South Africa. Read the interview.

Research into talcum powder – ovarian cancer link reveals troubling differences based on study designs
March 21, 2017: HemOnc Today interviews Dr. Paolo Boffeta regarding his team’s systematic review and meta-analysis evaluating the association between genital talcum powder use and ovarian cancer risk. Boffeta says that evidence falls short from demonstrating a casual link. Read the interview.

Hormonal maintenance therapy prolongs PFS for serous carcinoma of ovary, peritoneum
March 20, 2017: HemOnc Today interviews Dr. David Gershenson regarding the findings of a retrospective study that show “women with stage II to stage IV low-grade serous carcinoma of the ovary or peritoneum demonstrated longer PFS when treated with hormonal maintenance therapy after primary chemotherapy rather than routine observation.” Read the interview.

Hamad Medical Center holds first Qatar gynecologic malignancy symposium
March 20, 2017: The symposium addressed important issues in women’s cancer with a focus on the development of collaborative research and training in the GCC and MENA region. Read the press release.

Oral apixaban safe for thromboprophylaxis before surgery in gynecologic cancers
March 17, 2017:  Presented at SGO 2017 by Dr. Saketh Guntupalli, “Thromboprophylaxis with oral apixaban was similar to subcutaneous enoxaparin with regard to safety outcomes in women undergoing surgery for suspected gynecologic malignancies. The oral medication may provide an option that would increase compliance and satisfaction in this setting.” Read the CancerNetwork article.

Readmission rates after gynecologic surgery may not be a valid measurement of quality care
March 16, 2017: Two studies presented at SGO 2017 indicate “Surgeons should focus on long-term outcomes for the treatment of ovarian cancer rather than hospital readmission rates after surgery.” Read the article.

Priority symptoms identified in recurrent ovarian cancer
March 16, 2017: Presented at SGO 2017, the National Cancer Institute and National Academy of Sciences have identified 18 core symptoms that should be assessed among patients with recurrent OC. Read this news article to learn the symptoms.

Immunotherapy AXAL tops survival mark in cervical cancer
March 15, 2017: OncLive interviews Dr. Charles Leath III regarding immunotherapy, AXAL  which targets HPV-infected cells. The phase II study led to an unprecedented 1-year survival rate in patients with recurrent, metastatic cervical cancer. Read the interview.

Immunotherapy motolimod fails to improve survival in ovarian cancer
March 15, 2017: Data presented by Dr. Bradley Monk at SGO 2017: “The addition of the immune therapy motolimod to pegylated liposomal doxorubicin (PLD) failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial. There was a survival advantage, however, specifically in patients who experienced injection site reactions, which could help guide the use of this therapy.” Read the CancerNetwork article. 

Sentinel lymph node mapping cost-effective in endometrial carcinoma
March 15, 2017: “Sentinel lymph node (SLN) mapping is cost-effective compared with other methods of lymphadenectomy (LND) in the management of low-risk endometrial carcinoma, according to a decision analysis model study presented at the 2017 SGO Annual Meeting.” Read more.

Integrated molecular characterization of uterine carcinosarcoma
March 2017: This integrated genomic and proteomic analysis of 57 uterine carcinosarcomas provides insights into disease biology and offers therapeutic opportunities. Read the full text.

Advaxis presents oral late-breaking data on phase II GOG-0265 study of Axalimogene Filolisbac
March 15, 2017: Data presented at the 2017 SGO Annual Meeting: “Unprecedented 12-month survival rate for metastatic cervical cancer observed” Read the press release. Read the Medpage Today story on the same study.

Gene expression signature predicts outcomes in endometrial cancer
March 14, 2017: “A 7-transcript classifiers (MS7) effectively predicted metastatic disease for patients with endometrioid endometrial cancer (EEC), with added promise shown when the gene expression signature was combined with pathologic features, according to findings presented at the 2017 SGO Meeting.” Read more.

MMR deficiency linked to PD-L1 expression in endometrial cancer
March 14, 2017: “Mismatch repair (MMR)–deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors, according to a poster presentation at the 2017 SGO Annual Meeting.” Read more.

Reduction strategies improve surgical site infection rate after colon surgery
March 14, 2017: “Introduction of a surgical site infection (SSI) reduction bundle significantly improved 30-day SSI rates among gynecologic cancer patients undergoing colon surgery, according to a study presented at the 2017 SGO Annual Meeting.” Read more.

Niraparib maintenance results have paradigm-shifting potential in ovarian cancer
March 14, 2017:  Targeted Oncology interviewed Dr. Kathleen Moore and Dr. Ursula Matulonis at the 2017 SGO Annual Meeting,  discussing the use of PARP inhibitors such as niraparib for the treatment of ovarian cancer – advances that could be practice changing. Read the interview with Dr. Moore. Read the interview with Dr. Matulonis. 

Carboplatin desensitation leads to improved OS in ovarian cancer
March 14, 2017: Patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen had an improved overall survival (OS), according to a retrospective analysis reported at the 2017 SGO Annual Meeting on Women’s Cancer.” Read more.

Maintenance chemo after CR fails to extend survival in ovarian cancer
March 14, 2017: Presented at the 2017 SGO Annual Meeting on Women’s Cancer: “A long-term phase III randomized trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response (CR) to first-line therapy. Maintenance chemotherapy also increased toxicity in these patients.” Read more.

LYNPARZA™ (olaparib) phase III SOLO-2 data demonstrated progression-free survival benefit in BRCA-mutated ovarian cancer as maintenance therapy
March 14, 2017: AstraZeneca shares results of Phase III trial: “The SOLO-2 data demonstrated a statistically significant and clinically meaningful improvement in outcomes for those who took olaparib. The results, which showed a delay in disease progression in the maintenance setting, highlight the impact of PARP inhibition at the forefront of the important advances we are making in targeting ovarian cancer.” Read the full press release. Read the story. Read the MedPage Today story.

Enhanced Recovery after surgery for ovarian cancer patients
March 14, 2017: A interview with Dr. Robert Neff regarding his data presented at the 2017 SGO Annual Meeting on Women’s Cancer that compared the cost-effectiveness of an enhanced recovery program compared with usual care following patients who had surgical cytoreduction for their ovarian cancer. Read or listen to the interview.

Parents continue to see HPV vaccine as unnecessary and worry over its safety
March 13, 2017: In an effort to understand the relatively low uptake of the human papillomavirus (HPV) vaccine in the United States, a survey of parents of teenage girls has found that a lack of knowledge about the vaccine and a failure by healthcare providers to recommend it, superseded parental concern about their daughters’ not needing it because they are not sexually active. Read more about the survey results.

Three doses of HPV vaccine no more beneficial than two
March 13, 2017: Presented at SGO 2017, investigators observed no significant difference in outcomes between patients who received 2 doses of the vaccine and those who received 3 doses. Read the article.

Gynecologic Oncologists cite time, money as barriers to global health participation
March 12, 2017: “Lack of clinical coverage and time off topped the perceived hindrances to gynecologic oncologists’ participation in global health activities, according to a study reported at the Society of Gynecologic Oncology (SGO) in National Harbor, MD.” Read more.

Research shows vitamin B3 reduces pain from chemotherapy induced peripheral neuropathy
March 10, 2017: “Rats given prophylactic daily doses of nicotinamide riboside at 200 mg/kg 7 days prior to chemotherapy and continuing for 24 days after the termination of chemotherapy did not experience peripheral nerve hypersensitivity.” Read more.

Reversion mutations may predict chemotherapy response in recurrent serous ovarian cancer
March 7, 2017: “The detection of reversion BRCA1 or BRCA2 mutations among women with recurrent high-grade serous ovarian cancer predicted response to chemotherapy treatment, according to study results.” Read more.

Study shows platelets can deliver immunotherapy, reduce tumor regrowth
March 3, 2017: A new NCI study suggests that blood platelets engineered to deliver an immunotherapy drug may effectively eliminate cancer cells missed by surgery and prevent them from forming new tumors. Read the NCI blog.

Ovarian cancer target molecule may be key to blocking its spread
March 2, 2017: “Blocking a protein found on the surface of ovarian cancer cells could prevent or reduce the spread of the disease to other organs, according to new research.” Read more.

The Pap smear: groundbreaking, lifesaving  – and obsolete?
March 1, 2017: With new ways to collect data, including HPV testing, is the Pap past it’s prime? Read more.

Lowering GI Toxicities in Gynecologic Cancers
March 1, 2017: “Intensity-modulated radiation therapy (IMRT) proved to lower the incidence of gastrointestinal toxicities in patients with gynecologic malignancies, according to the results from a recent study.” Read more.

NEJM: The changing face of clinical trials
March 2017: A collection of articles that examine the current challenges in the design, performance, and interpretation of clinical trials. Read the collection.

Controlled interventions to reduce burnout in physicians: a systematic review and meta-analysis
February 2017:  This meta-analysis of 20 controlled interventions on 1550 physicians found that existing interventions were associated with small and significant reductions in burnout. The strongest evidence for effectiveness was found for organization-directed interventions, but these interventions were rare. Read more.

Special issue in Clinical Oncology: Radiotherapy in low and middle income countries
February 2017: the Feb. special issue of Clinical Oncology includes an editorial and several studies and analysis of radiotherapy in low and middle income countries. See the issue.

Ovarian cancer screening has some benefits in high-risk women
February 28, 2017: “Screening for ovarian cancer in high-risk patients led to detection of significantly more early-stage disease as compared with the 1 year after screening ended, a multicenter study showed.” Read more.

Evolution of surgical management optimizes care for patients with rare gynecologic tumors
February 25, 2017:  This commentary reiterates that “significant progress has been made in the treatment of rare gynecologic cancers over the past decade, and clinicians should be aware of these advances in order to provide optimal patient care.” Read more.

Low recurrence after risk-reducing surgery for BRCA carriers
February 24, 2017: Dr. Maurie Markman discusses a paper that appeared in the journal Gynecologic Oncology, entitled “Occult and Subsequent Cancer Incidence Following the Risk-Reducing Surgery in BRCA Mutation Carriers.” Read more.

Researcher finds safer, less invasive method of staging endometrial cancer
February 24, 2017: “Emma Rossi, MD, in the UNC Department of Obstetric and Gynecology’s Division of Gynecologic Oncology, has published a study in Lancet Oncology online that identifies sentinel-lymph-node mapping as a safer and less-invasive method of staging endometrial cancer that is equally as accurate as the more traditional lymphadenectomy.” Read more.

Researchers use genetics to identify cancer recurrence risk
February 22, 2017:  University of Wisconsin-Madison researcher, Christine Kendziorski and her team of researchers have identified a set of genetic traits that indicate a person may have a relapse of ovarian cancer. Read more.

Hormonal maintenance therapy may improve survival in women with chemo-resistant rare ovarian or peritoneum cancer
February 21, 2017: For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance therapy (HMT) may significantly improve survival, according to a new study from researchers at The University of Texas MD Anderson Cancer Center. Read more.

Read archived news stories.

World Ovarian Cancer Day

Ovarian cancer is the seventh most commonly diagnosed cancer in women worldwide with over 250,000 new cases a year. May 8, 2017 is the 5th World Ovarian Cancer Day – a day in which organizations around the world unite to educate their communities about ovarian cancer and its symptoms. Education and awareness continue to be our best defense against this devastating disease. IGCS is committed to raising awareness to early diagnosis and to reducing the burden of ovarian cancer by ensuring clinicians and women are fully informed about  symptomatology and the benefits of prophylactic surgery in high risk women.

This day provides us with an excellent opportunity to amplify the conversation among IGCS Members who conduct research in the prevention and treatment of ovarian cancer, especially considering the number of breakthroughs regarding ovarian treatment therapies over the last several years. The IGCS Education Committee has selected the following new Education Exchange video clips to release on World Ovarian Cancer Day including:

  • Roberto Angioli discussing ovarian cancer follow-up strategies and clinical uses of tumor markers.
  • Ayelet Shai discussing her abstract presented at IGCS 2016 “The effect of aspirin, statins, metformin and metabolic co-morbidities on the prognosis of patients with ovarian cancer
  • Jalid Sehouli discussing biomarkers in ovarian cancer immunotherapy clinical trials
  • Ignace Vergote discussing his abstract presented at IGCS 2016 “Meta-analysis of the randomized EORTC and chorus neoadjuvant vs. primary debulking trials in advanced tubo-ovarian cancer.

IGCS continues to make education and training top priorities and hope that you have taken the time to view some of the additional excellent education in ourmember education portal. unites advocacy groups worldwide and provides excellent resources for patient materials including key symptoms and risk factors for ovarian cancer and personal stories from dozens of survivors. We encourage you to review these informative materials and share them with your colleagues, patients and communities.

As we continue to strive to be THE global gynecologic oncology organization, we are confident that each of you will continue to play a vital role in continuing to increase the care for women afflicted with gynecologic cancers. We must continue to challenge ourselves and strive to be an impactful organization in relieving the burden of cancer globally.
We look forward to our continued partnership with you, our members. Together, we are better.
Michael Quinn, AM, MGO
IGCS President 
Mary Eiken, RN, MS

Read the Current Issue of IJGC


IJGC is the scientific publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a multidisciplinary approach, and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. The list of associate editors represents every part of the globe and all the major disciplines involved in treating cancer. Preview the current issue (May, 2017) table of contents here.

IGCS Members
Sign in to the IGCS Member Portal and click through to the Journal to gain full access to the articles.

N0t an IGCS Member?
Join today to obtain online access to IJGC.

Education Portal Access

Four new Education Exchange videos related to endometrial cancer have been uploaded to the IGCS Education Portal:

  1. Dr. Walter Gotlieb expands on the topic: How Might  Sentinel Lymph Node Dissection Change The Outcome For Endometrial Cancer?
  2. Dr. Remi Nout discusses his abstract presented at IGCS 2016: Vaginal Brachytherapy Versus External Beam Pelvic Radiotherapy For High-Intermediate Risk Endometrial Cancer: Long Term Results Of The Randomized Portec-2 Trial
  3. Dr. Andreas Obermair discusses his abstract presented at IGCS 2016: Disease-Free And Overall-Survival After Total Laparoscopy Versus Open Abdominal Hysterectomy For Early Stage Endometrial Cancer: Results From The LACE Trial
  4. Dr. Pamela Soliman discusses her abstract presented at IGCS 2016: Sentinel Lymph Node Mapping Accurately Identifies Positive Nodes In Women With High Risk Endometrial Cancer: A Prospective Validation Trial

Education Portal Navigation Tutorial

This brief video will show you the step-by-step navigation to access the IGCS Education Portal to find the above Education Exchange video clips and much more!

To access the portal, click on the “members” button at the top right of the IGCS website, sign in and then click “Education Portal.” In the IGCS education portal, members will find:
  • Webcasts from the 2016 and 2014 Biennial Meetings
  • Surgical videos that were playing in the exhibit hall during the 2016 Biennial Meeting
  • Education Exchange videos
  • Blogs written by members of the committee providing commentary on articles published in the International Journal of Gynecological Cancers

IGCS Council Report

Dear IGCS Members,

The International Gynecologic Cancer Society (IGCS) Council is responsible for the operational, strategic, and financial performance of the Society, ensuring that the actions taken achieve the mission and vision of our organization. Recently, the Council held a regularly scheduled meeting in Washington, DC and we would like to communicate the following summary of that meeting.

The organizational strategic plan was reviewed by members of Council and it was agreed that activities of the Society would be aligned to all aspects of the strategic plan moving forward. The strategic plan is a simple but direct plan focusing on membership needs and growth, financial strength and organizational structure and capacity.

We are beginning to build collaborative partnerships and relationships with many organizations throughout the world. The Council believes these relationships will proliferate and continue to raise the profile of our specialty and IGCS. As we build these partnerships, the Council will appoint members of the Society to serve as liaisons between us and our partner organizations, representing IGCS interests at meetings pertaining to gynecologic oncology.

Similarly, the Council felt it was important to continue to strengthen ties with the European Society of Gynaecological Society (ESGO). The Council discussed ways both societies could collaborate on projects that are of interest to both memberships. The Council concluded that continuing to seek ways to partner with ESGO would only benefit our members and patients.

Council was presented with some exciting data and statistics on our new website and our recent communications to the membership. We reviewed the top countries accessing the site, the number of pages being viewed and the areas of interest on the site. The Council was encouraged by this new level of member engagement and the amount of communication provided.

Council revisited IGCS member benefits including our education and training offerings and our capacity to reach our members all over the globe through in-person meetings, our new web portal and collaboration with other organizations through joint meetings. Council charged the Executive Committee and staff with continuing to explore more educational opportunities to benefit you, the members.

The relationship with the publisher of  the International Journal of Gynecological Cancer was discussed and we are confident that this relationship will continue to be strong and mutually beneficial to everyone. The Council is also encouraged about the responses gathered in response to the current search for the new Editor-in-Chief.

Council approved twenty new members into the Society and discussed the need for further diversification within the membership, specifically to ensure gender representation on the Council. It was agreed that continued mentorship and leadership opportunities were paramount to the success of gender diversification. The concept of an International Young Doctor Network was discussed and approved, recognizing the future of IGCS is in the strength of our young trainees and practitioners.

Council was also presented with new ideas and concepts about member expansion. It was the consensus of the Council that IGCS look to develop an alliance with organizations whose objectives are consistent and aligned with our own. These membership partnerships will bring together the leaders and members of organizations from all over the globe, allowing for closer dialogue and a forum for sharing information and ideas to find solutions to the many issues that face us in gynecologic oncology. We are excited to share more about this program in the coming weeks.

Finally, Council was presented a detail financial review of the year-end 2016 financials along with a look ahead at 2017. We were grateful for the scientific and financial success of the 2016 Biennial Meeting in Lisbon and we look forward to your continued participation in our future educational offerings.

The Treasurer expressed concern about unpaid member dues. If you have not paid your 2017 dues, we strongly encourage you to do so in the next week as unpaid memberships will result in discontinuation of access to our member area on the website, journal and other benefits by April 15th.

We are confident that a large increase in IGCS activity has been evident over the course of this past year. The Council acts in the best interests of the Society and is more engaged than ever in setting the current and future course of our specialty. On your behalf, we thank them for their ongoing commitment.

We welcome your feedback on ways to continually improve your Society. Should you wish to contact either of us, please email us at and

Michael Quinn, AM, MGO
IGCS President 
Mary Eiken, RN, MS

2017 Membership Renewal

Unpaid members: Please submit payment for 2017 membership dues by April 15, 2017 to avoid deactivation


Attention current IGCS members: to continue your member benefits and online access to the International Journal of Gynecological Cancer, please submit your 2017 dues payment.

  1. Login here: 
  2. Your username is the email address we have on file for you.
  3. Your default password is: unite. (If you have logged into the new IGCS website and changed your password since October 28, 2016, please use that password.)

If you do not wish to pay online, you may submit payment by mailing in a check or money order. Please email for assistance with an invoice.

Thank you in advance for your payment. IGCS values your participation and commitment to the society.


Niraparib FDA approved

The U.S. Food & Drug Administration has approved ZEJULA™ (niraparib) for the maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer following a complete or partial response to a platinum-based chemotherapy regimen. ZEJULA is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancer.

Read the Tesaro news release

Review the full prescribing information.

ASCO Resource-Stratified Guideline

ASCO’s Resource-Stratified Cervical Cancer Prevention Guideline

“Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline,” was published Friday, March 17, 2017 in Journal of Global Oncology.

The purpose of the guideline is to provide resource-stratified (four tiers), evidence-based recommendations on the primary prevention of cervical cancer globally.  Supplements, a slide set and other resources are also available for download.

View the guideline and additional materials.

A special recognition to IGCS members Neerja Bhatla, Ryo Konno and Isaac Folorunso Adewole who participated in the creation of this guideline and materials.